GSK has applied to the US Food and Drug Administration (FDA) to extend use of its respiratory syncytial virus (RSV) vaccine Arexvy to adults under the age of 50 who are at increased risk of the ...

If approved in the world's biggest pharmaceuticals market, GSK's vaccine, Arexvy, would be competing for a market share in ...

The Food and Drug Administration has approved three vaccines for RSV — GSK's GSK.L Arexvy, Moderna's MRNA.O mRESVIA and ...

Moderna rises as CDC expands RSV vaccine guidance to include high-risk adults aged 50-59, boosting mResvia's reach.

FDA accepts GSK's filing to extend Arexvy's RSV vaccine use to high-risk adults under 50, with a decision due in 2026.

The offering, the first IPO this year, attracted more than 32 billion dirhams ($3.5 bln) in demand for 500 million dirhams in shares. GSK seeks FDA nod for expanded use of RSV vaccine in adults ...

Health Secretary Robert F. Kennedy Jr. endorsed the expanded use of RSV vaccines for people 50 through 59 years old who are ...

The high court sides with HHS on HIV PrEP drugs; Health Secretary RFK Jr.’s newly appointed CDC vaccine advisors discuss thimerosal in flu vaccines, skip vote on Moderna’s mRNA-based RSV vaccine; FDA ...

Research shows RSV leads to high hospitalization rates in adults, emphasizing the importance of enhanced surveillance and ...

Gilead has blamed the low rate of respiratory syncytial virus infections last season for ending two midstage trials of obeldesivir.

The U.S. Centers for Disease Control and Prevention has accepted recommendations made by an advisory panel in April on the use of respiratory syncytial virus vaccines in adults aged between 50 and 59 ...